IDN

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

The Wetrich Group Announces Executive Leadership Transitions

Retrieved on: 
Wednesday, February 14, 2024
PCC, BSN, Building, Growth, IDN, ICF, National accounts, RPC, GPO, Management

Southlake, TX, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Wetrich Group LLC, a comprehensive advisory and consulting firm focused on the health care industry, has announced the appointment of Carl Meyer as President, who will succeed James G. Wetrich, effective immediately.

Key Points: 
  • Southlake, TX, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Wetrich Group LLC, a comprehensive advisory and consulting firm focused on the health care industry, has announced the appointment of Carl Meyer as President, who will succeed James G. Wetrich, effective immediately.
  • Meyer joined The Wetrich Group in 2013, and most recently served as Executive Vice President.
  • While at BSN, he assisted the organization's transition from a direct supply chain to a distribution centric and group purchasing aligned organization.
  • Following his departure from The Wetrich Group, Wetrich will transition to a CEO Mentor role with Building Champions, a professional training and coaching organization headquartered in Lake Oswego, Oregon.

Promaxo Announces System Sales for 2023

Retrieved on: 
Thursday, January 4, 2024
IRE, Robotics, Marketing, FDA, AI, ASC, MRI, Hospital, Cryotherapy, IDN, Medical imaging

OAKLAND, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced sales of 69 systems for the full year ended December 31, 2023.

Key Points: 
  • OAKLAND, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced sales of 69 systems for the full year ended December 31, 2023.
  • System sales were made through the Company’s various sales programs to physician practices, ambulatory surgery centers (ASC), and integrated delivery network (IDN) facilities.
  • “With full year 2023 sales of 69 systems ahead of our target 60 systems and up from 23 systems sold in the year ago period, we capped 2023 on positive momentum, fueling our expectations for strong, steady growth in 2024,” said Dr. Amit Vohra, Founder and CEO of Promaxo.
  • We are executing well on our growth agenda, with strategic investments made in our sales and marketing organization, as well as sales programs, to drive continued market penetration of our portable Promaxo MRI system.”
    Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo MRI system.

Orsini selected as the exclusive specialty pharmacy for WAINUATM (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy

Retrieved on: 
Thursday, January 4, 2024
Vitamin A deficiency, ELK, AstraZeneca, IDN, FDA, Disease, Ionis, Orsini, Serum, Polyneuropathy, Internationalized domain name, Vitamin A, Pharmacy, Patient, Diagnosis, Disability studies, Amyloidosis

ELK GROVE VILLAGE, Ill., Jan. 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy ("Orsini") has been selected by AstraZeneca and Ionis as the exclusive specialty pharmacy partner for WAINUA™ (eplontersen), an FDA-approved treatment for adults living with hereditary transthyretin-mediated amyloid polyneuropathy (commonly referred to as hATTR-PN or ATTRv-PN).

Key Points: 
  • ELK GROVE VILLAGE, Ill., Jan. 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy ("Orsini") has been selected by AstraZeneca and Ionis as the exclusive specialty pharmacy partner for WAINUA™ (eplontersen), an FDA-approved treatment for adults living with hereditary transthyretin-mediated amyloid polyneuropathy (commonly referred to as hATTR-PN or ATTRv-PN).
  • "Orsini is proud to be the exclusive specialty pharmacy offering access to WAINUA as a new treatment option for patients living with ATTRv-PN," Orsini CEO Brandon Tom said.
  • Indication: WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
  • Note: While Orsini is the exclusive specialty pharmacy partner for WAINUA, it may also be available for use by integrated delivery networks (IDNs) within qualifying IDN-owned specialty pharmacies.

Event Report: The Winner of the Dream Championship 2023 World Tournament is IDN | Vile from Indonesia

Retrieved on: 
Wednesday, November 22, 2023
Dream, IDN

Out of all of the competitors from around the world, IDN | Vile from Indonesia rose to become the champion of 2023.

Key Points: 
  • Out of all of the competitors from around the world, IDN | Vile from Indonesia rose to become the champion of 2023.
  • In the video, the prize for first place was revealed to be a special illustration gifted by Yoichi Takahashi himself.
  • Aside from the illustration, IDN | Vile will also receive other rewards such as special in-game items for the Dream Championship 2023 champion, as well as a championship trophy.
  • The intense battle that ensued in the Dream Championship 2023 Final Tournament is currently available to watch in the YouTube channel archive.

Visage Soars with CloudPACS at RSNA 2023

Retrieved on: 
Thursday, November 9, 2023
Cloud, ASX, RSNA, Radiological Society of North America, Education, Cardiac catheterization, PACS, Load balancing (computing), MD, Breast, Pathology, Python, Health, Research, Artificial intelligence, Workflow, FHIR, Journey, Ecosystem, PME, GPU, IDN, Algorithm, Imaging, AI, Neuroimaging Informatics Technology Initiative, SAN, Software as a service, Nightclub, Medical imaging, Medical device, Echocardiography, Radiology, Visage, Cardiology

SAN DIEGO, Nov. 9, 2023 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced it will be showcasing a series of exciting new product additions and innovations, as well as the industry-leading Visage® 7 Enterprise Imaging Platform ("Visage 7"), engineered for CloudPACS (cloudpacs.com™) at the Radiological Society of North America (RSNA) 2023 annual meeting, Booth 4329, McCormick Place South Hall (Chicago, IL) from Sunday, November 26 – Wednesday, November 29, 2023.

Key Points: 
  • At RSNA 2023, in addition to demonstrating the breadth of the Visage 7 platform, Visage is introducing multiple new solutions and offering customer insights into Visage 7, including:
    Visage 7 | Cardiology Imaging.
  • In the Visage booth, Visage will be demonstrating Visage Breast Density and numerous AI algorithms based on Visage AI Accelerator* global customer research collaborations, as well as third-party AI solutions.
  • To schedule a priority demonstration of Visage 7 at RSNA 2023, please click here for additional details.
  • If you are unable to attend RSNA 2023, but would like to schedule a demonstration of Visage 7, please click here .

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

Promaxo Announces Sale of 20 Systems in the Third Quarter 2023

Retrieved on: 
Monday, October 2, 2023
ASC, IDN, Summit Health, Sale, MRI, Hospital, Rhode Island Hospital, Alpert Medical School, Growth, AI, Robotics, FDA, Urology, Nursing

OAKLAND, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced the sale of 20 systems in the third quarter ending September 30, 2023.

Key Points: 
  • OAKLAND, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced the sale of 20 systems in the third quarter ending September 30, 2023.
  • Promaxo has sold a total of 52 systems through the first nine months of 2023, compared to 13 systems during the same prior year period.
  • The Company has sold a total of 77 systems across 26 states since its commercial launch in the fourth quarter of 2021.
  • “We are happy to announce another quarter of great execution,” said Dr. Amit Vohra, Founder and CEO of Promaxo.

UnityPoint Health and Iowa Donor Network Launch InVita Healthcare Technologies' iReferral to Increase Donation and Transplantation in Iowa

Retrieved on: 
Tuesday, September 26, 2023
OPO, Centers for Medicare & Medicaid Services, IDN, Partnership, CMS, UnityPoint Health, CFR, Medicare, Patient, Nursing, Organ procurement organization, Health, Medical device, Pharmaceutical industry

DES MOINES, Iowa, Sept. 26, 2023 /PRNewswire/ -- InVita Healthcare Technologies, UnityPoint Health, and Iowa Donor Network ("IDN"), the federally designated Organ Procurement Organization (OPO) serving the state of Iowa, have collaborated to successfully launch iReferral℠ across thirteen (13) UnityPoint Health hospital facilities across Iowa in August 2023.  iReferral℠ replaces the prior time-intensive, error-prone, and manual telephonic referral process with healthcare interoperability technology that automatically identifies potential organ and tissue donors based on established criteria and securely delivers donor referrals to IDN's iTransplant℠ System.

Key Points: 
  • "We are honored to be a part of this collaboration and to implement iReferral across UnityPoint Health.
  • "We are thankful to UnityPoint Health for their partnership and commitment to saving more lives through organ donation by implementing iReferral system wide.
  • The use of iReferral will help ensure more potential organ donors are referred to Iowa Donor Network in a timely manner.
  • "We are proud to work with Iowa Donor Network and Unity Point Health to launch iReferral℠ across their extensive hospital network," said Todd Collins, President & CEO of InVita Healthcare Technologies.